title: Antibody fusions with immunomodulatory proteins for cancer therapy.
abstract: The potential of immunomodulatory proteins, in particular cytokines, for cancer therapy is well recognized, but hampered by the toxicity associated with their systemic application. In order to address this problem, targeted delivery by antibody fusion proteins has been early proposed and their development intensively pursued over the last decade. Here, factors influencing the selection and modification of cytokines and antibody formats for this approach are being discussed, indicating current developments and translational advances in the field.
authors.affiliation: Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany. Electronic address: dafne.mueller@izi.uni-stuttgart.de.
authors.forename: Dafne
authors.initials: D
authors.lastname: Müller
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology*; D016207:Cytokines / Q000276:immunology*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D018836:Inflammation Mediators / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000276:immunology*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D018836:Inflammation Mediators; D011993:Recombinant Fusion Proteins
keywords: Antibody–cytokine fusion proteins; Immunocytokines; Targeted cancer immunotherapy